|
|
|
1-10 employees
View all
|
|
Biotechnology
|
|
1790 E River Rd, Suite 205, Tucson, Arizona 85718, US
|
|
Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension. Effective FDA-approved drugs are either currently unavailable or extraordinarily modest in their ability to modify disease progression. No drug is currently available that is preventive or curative. Aqualung’s strategies, which include deployment of a human monoclonal antibody which targets a novel inflammatory mediator (nicotinamide phosphoribosyltransferase or NAMPT) will address the unmet need for novel, effective therapies for VILI, IPF, and pulmonary hypertension.
|
AQUALUNG THERAPEUTICS CORPORATION Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used AQUALUNG THERAPEUTICS CORPORATION email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact AQUALUNG THERAPEUTICS CORPORATION customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.